专门痴呆症护理,COVID-19和中枢神经系统药物使用在辅助生活中的关联:基于人口的重复横截面研究
Colleen J Maxwell1,2, Hana Dampf3, Jillian P Squires4
1School of Pharmacy, University of Waterloo, 200 University Avenue West, Waterloo, ON, N2L 3G1, Canada. colleen.maxwell@uwaterloo.ca.
BMC geriatrics
|August 14, 2024
概括
在COVID-19大流行期间,抗精神病和抗抑郁药的使用在辅助生活 (AL) 居民中增加,特别是那些在痴呆症护理机构中的居民,这引发了安全问题.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 辅助生活 (AL) 是痴呆症患者的常见环境.
- 由于人员和服务水平较低,人们对AL的护理质量存在担忧.
- COVID-19 流行病可能影响了AL居民认知障碍患者的药物使用.
研究的目的:
- 检查AL设置 (痴呆症护理与其他) 和COVID-19波对痴呆症/认知障碍居民药物使用的相关性.
- 探索与普遍药物使用相关的居民和家庭特征.
- 分析抗精神病药物,抗抑郁药物,抗痴呆药物,二类药物和抗药物的使用趋势.
主要方法:
- 在加拿大阿尔伯塔省 (2018-2021) 使用链接的行政数据库进行基于人口的重复横截面研究.
- 检查了季度药物分配给患有痴呆症/认知障碍的AL居民,跨越大流行浪潮.
- 使用日志双项GEE模型来估计流行率,根据居民和家庭特征进行调整.
主要成果:
- 抗精神病药物的使用在第二到第四波大流行期间增加,在第三和第四波期间,痴呆症护理设置的增加更为明显.
- 在这两种情况下,抗抑郁药的使用量略有增加,而二甲的使用量则有所下降.
- 在几次大流行浪潮期间,GABAPENTINOID的使用在痴呆症护理AL居民中显著增加.
结论:
- 在大流行期间,AL居民使用抗精神病和抗抑郁药的持续增加令人担忧.
- 在痴呆症护理环境中抗精神病药和 gabapentinoid 的使用量大幅增加值得关注.
- 这些药物趋势凸显了AL认知障碍患者的潜在风险.
相关概念视频
01:30Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
111
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
111
01:30Cognitive Development During Adulthood
72
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
72
01:29Documentation in Long-Term and Home Healthcare Setting
875
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
875